103 related articles for article (PubMed ID: 11449307)
1. Expression of c-erbB-2, p53 and c-myc proteins in male breast carcinoma: Comparison with traditional prognostic factors and survival.
Mourão Netto M; Logullo AF; Nonogaki S; Brentani RR; Brentani MM
Braz J Med Biol Res; 2001 Jul; 34(7):887-94. PubMed ID: 11449307
[TBL] [Abstract][Full Text] [Related]
2. Oncogenes and male breast carcinoma: c-erbB-2 and p53 coexpression predicts a poor survival.
Pich A; Margaria E; Chiusa L
J Clin Oncol; 2000 Aug; 18(16):2948-56. PubMed ID: 10944127
[TBL] [Abstract][Full Text] [Related]
3. Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma.
Bland KI; Konstadoulakis MM; Vezeridis MP; Wanebo HJ
Ann Surg; 1995 Jun; 221(6):706-18; discussion 718-20. PubMed ID: 7794075
[TBL] [Abstract][Full Text] [Related]
4. Comparative study of tumor angiogenesis and immunohistochemistry for p53, c-ErbB2, c-myc and EGFr as prognostic factors in gastric cancer.
Sanz-Ortega J; Steinberg SM; Moro E; Saez M; Lopez JA; Sierra E; Sanz-Esponera J; Merino MJ
Histol Histopathol; 2000 Apr; 15(2):455-62. PubMed ID: 10809364
[TBL] [Abstract][Full Text] [Related]
5. Angiogenesis, p53, and c-erbB-2 immunoreactivity and clinicopathological features in male breast cancer.
Shpitz B; Bomstein Y; Sternberg A; Klein E; Liverant S; Groisman G; Bernheim J
J Surg Oncol; 2000 Dec; 75(4):252-7. PubMed ID: 11135266
[TBL] [Abstract][Full Text] [Related]
6. Relationship between AgNORs, MIB-1 and oncogene expression in male breast carcinoma and papillary superficial bladder neoplasm.
Pich A; Margaria E; Chiusa L; Bortolin P; Palestro G
Oncol Rep; 2003; 10(5):1329-35. PubMed ID: 12883702
[TBL] [Abstract][Full Text] [Related]
7. Molecular biomarkers for breast cancer prognosis: coexpression of c-erbB-2 and p53.
Beenken SW; Grizzle WE; Crowe DR; Conner MG; Weiss HL; Sellers MT; Krontiras H; Urist MM; Bland KI
Ann Surg; 2001 May; 233(5):630-8. PubMed ID: 11323501
[TBL] [Abstract][Full Text] [Related]
8. Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases.
Wang-Rodriguez J; Cross K; Gallagher S; Djahanban M; Armstrong JM; Wiedner N; Shapiro DH
Mod Pathol; 2002 Aug; 15(8):853-61. PubMed ID: 12181271
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of p53, c-erbB-2 and epidermal growth factor receptor on head and neck carcinoma.
Parise Junior O; Carvalho LV; Miguel RE; Kowalski LP
Sao Paulo Med J; 2004 Nov; 122(6):264-8. PubMed ID: 15692721
[TBL] [Abstract][Full Text] [Related]
10. Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy.
Archer SG; Eliopoulos A; Spandidos D; Barnes D; Ellis IO; Blamey RW; Nicholson RI; Robertson JF
Br J Cancer; 1995 Nov; 72(5):1259-66. PubMed ID: 7577479
[TBL] [Abstract][Full Text] [Related]
11. c-erbB-2, p53 protein expression and steroid hormone receptors in breast carcinomas: an immunohistochemical study.
Yokota T; Imamura M; Teshima S; Suzuki H; Tezuka F; Kikuchi S; Kunii Y; Yamauchi H
Anticancer Res; 1999; 19(5B):4007-12. PubMed ID: 10628345
[TBL] [Abstract][Full Text] [Related]
12. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.
Soda G; Antonaci A; Bosco D; Nardoni S; Melis M
J Exp Clin Cancer Res; 1999 Sep; 18(3):363-7. PubMed ID: 10606183
[TBL] [Abstract][Full Text] [Related]
13. Oncogenes in male breast cancer.
Idelevich E; Mozes M; Ben-Baruch N; Huszar M; Kruglikova A; Katsnelson R; Shani A
Am J Clin Oncol; 2003 Jun; 26(3):259-61. PubMed ID: 12796596
[TBL] [Abstract][Full Text] [Related]
14. Expression of tissue inhibitor of matrix metalloproteinases (TIMP)-3 protein in invasive breast carcinoma: relation to tumor phenotype and clinical outcome.
Mylona E; Magkou C; Giannopoulou I; Agrogiannis G; Markaki S; Keramopoulos A; Nakopoulou L
Breast Cancer Res; 2006; 8(5):R57. PubMed ID: 17032447
[TBL] [Abstract][Full Text] [Related]
15. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients.
Isola J; Visakorpi T; Holli K; Kallioniemi OP
J Natl Cancer Inst; 1992 Jul; 84(14):1109-14. PubMed ID: 1352359
[TBL] [Abstract][Full Text] [Related]
16. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer.
Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
Anticancer Res; 1997; 17(2B):1417-23. PubMed ID: 9137508
[TBL] [Abstract][Full Text] [Related]
17. Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis.
Kersemaekers AM; Fleuren GJ; Kenter GG; Van den Broek LJ; Uljee SM; Hermans J; Van de Vijver MJ
Clin Cancer Res; 1999 Mar; 5(3):577-86. PubMed ID: 10100709
[TBL] [Abstract][Full Text] [Related]
18. Expression of c-myc, erbB-2, p53 and nm23-H1 gene product in benign and malignant breast lesions: coexpression and correlation with clinicopathologic parameters.
Sirotkovic-Skerlev M; Krizanac S; Kapitanovic S; Husnjak K; Unusic J; Pavelic K
Exp Mol Pathol; 2005 Aug; 79(1):42-50. PubMed ID: 16005711
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of ER, PR, Ki67, c-erbB-2, and p53 in endometrial carcinoma.
Suthipintawong C; Wejaranayang C; Vipupinyo C
J Med Assoc Thai; 2008 Dec; 91(12):1779-84. PubMed ID: 19133508
[TBL] [Abstract][Full Text] [Related]
20. p53 and c-erbB-2 but not bcl-2 are predictive of metastasis-free survival in breast cancer patients receiving post-mastectomy adjuvant radiotherapy in Taiwan.
Chen HH; Su WC; Guo HR; Chang TW; Lee WY
Jpn J Clin Oncol; 2002 Sep; 32(9):332-9. PubMed ID: 12417598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
